Targeting metabolic activity in high-risk neuroblastoma through Monocarboxylate Transporter 1 (MCT1) inhibition

por Khan, Aaminah, Valli, Emanuele, Lam, Hayley, Scott, David A., Murray, Jayne, Eden, Georgina, Gamble, Laura D., Pandher, Rupinder, Flemming, Claudia L., Allan, Sophie, Osterman, Andrei L., Haber, Michelle, Norris, Murray D., Fletcher, Jamie I., Yu, Denise M.T.
Publicado en Oncogene (2020)

Plasma metabolomic changes following PI3K inhibition as pharmacodynamic biomarkers: preclinical discovery to Phase I trial evaluation

por Ang, Joo Ern, Pandher, Rupinder, Ang, Joo Chew, Asad, Yasmin J, Henley, Alan, Valenti, Melanie, Box, Gary, de haven Brandon, Alexis, Baird, Richard R., Friedman, Lori, Derynck, Mika, Vanhaesebroeck, Bart, Eccles, Suzanne A, Kaye, Stan B, Workman, Paul, de Bono, Johann S, Raynaud, Florence I
Publicado en Mol Cancer Ther (2016)